Heineken has issued a stark warning to the hospitality industry: the rising popularity of GLP-1 weight-loss drugs could fundamentally alter how much beer people drink. In a document presented to UK pub and bar owners earlier this month, the Dutch brewer advised that these medications—originally developed for diabetes but now widely used for weight management—may lead to a noticeable drop in consumption.
According to a Reuters report, Heineken's guidance suggests that GLP-1 users often experience a sense of fullness and reduced appetite, which translates into fewer and smaller servings of beer. The company's research indicates a broader shift toward moderation, with consumers increasingly opting for half-pints, lower-alcohol brews, and premium products.
"We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," a Heineken spokesperson told Reuters. The company is positioning itself to adapt, recommending that venues expand their offerings of no- and low-alcohol options.
However, not all brewers are rushing to embrace a GLP-1-centric strategy. Damm's UK managing director, Luke White, expressed caution, noting the regulatory hurdles and the need for accurate marketing claims. "It's really hard for a beer company to do that because of legislative reasons and making sure your claims are right, so I wouldn't say that we would actively pursue a GLP-1-focused strategy," he said.
Instead, Damm is focusing on the growing segments of no-and-low and world lager in the UK. "We're quite nicely positioned where in our portfolio, in the UK specifically, the two growing areas in the category are no-and-low and world lager," White added. "We will be spending a lot more time on the development of the low-and-no sector, be that flavor or new ABV."
The potential impact is backed by data. A study by Drinkaware and KAM found that people using GLP-1 medications reduced their spending on alcohol at pubs, bars, and restaurants by 30 percent, and their weekly alcohol purchases for home consumption fell by 22 percent. These figures underscore a significant behavioral shift that could reshape the beer market.
Other major brewers, including Diageo and Carlsberg, have also taken note, though their public responses have been more measured. The industry as a whole is grappling with how to respond to a trend that aligns with broader health and wellness movements but threatens traditional revenue streams.
For policymakers and investors, the implications are clear: as GLP-1 drugs become more widespread, the beverage industry may need to innovate or face declining sales. The shift toward moderation is not new, but the acceleration driven by these medications could be a game-changer.
